đź“ŁZent2U is happy to announce a successful finalization of a harmonized part of the registration procedure with European authorities for Apremilast film-coated tablets in 10mg, 20mg, and 30mg strengths. This achievement marks a significant milestone in the process of obtaining Marketing Authorization across European countries.
💊 Apremilast developed by Zentiva is a generic alternative to the medication Otezla® by Celgene® indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy as well as for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
🤝Zent2U is progressing in our strive to provide our partners with high-quality and cost-effective products to enrich their portfolio of immunomodulating medications and allow our partners to launch in the first generic wave.
📧Partner up now and connect with our team today!
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda – Key Account Manager B2B Europe
yuliyana.manolova@zentiva.com – Yuliyana Manolova – Head of Distribution and Clinical Trials
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
#psoriaticarthritis #plaquepsoriasis #B2B #Zent2U #Zentiva
